Agilent to Acquire Assets from ABC Instrumentacion Analitica
Agilent Technologies Inc. (Santa Clara, California) and ABC Instrumentacion Analitica (ABCIA) (Mexico City, Mexico) have signed a definitive agreement for Agilent to acquire assets from ABCIA.
Agilent Technologies Inc. (Santa Clara, California) and ABC Instrumentación Analítica (ABCIA) (Mexico City, Mexico) have signed a definitive agreement for Agilent to acquire assets from ABCIA. Privately held ABCIA is a distributor of analytical solutions, including Agilent’s chemical analysis and life science products.
The acquisition is expected to be completed on October 1. Once completed, former ABCIA customers in Mexico will have access to an integrated sales and service portfolio directly from Agilent.
ABCIA provides sales, application support, and customer training for Agilent products such as gas and liquid chromatographs, mass spectrometers, atomic and molecular spectroscopy systems, and bioanalysers.
Agilent and ABCIA have been partners for more than two decades. About 30 ABCIA employees are expected to transfer to Agilent when the acquisition is final.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
